Stocks Comparison
Charles River Laboratories International vs Incyte: revenue, profit, margins and growth compared
Charles River Laboratories International brought in $4B of revenue in fiscal 2025, Incyte $5.1B in fiscal 2025. Revenue changed by -0.9% at Charles River Laboratories International and +21.2% at Incyte on the year before, so Incyte grew faster. Charles River Laboratories International kept -3.6% of its revenue as net profit, Incyte 25.0%.
Side by side, latest fiscal year
| CRL | INCY | |
|---|---|---|
| Fiscal year ended | FY2025 (December 27, 2025) | FY2025 (December 31, 2025) |
| Revenue | $4B | $5.1B |
| Revenue growth | -0.9% | +21.2% |
| Net income | -$144.3M | $1.3B |
| Net margin | -3.6% | 25.0% |
| Free cash flow | $518.5M | n/a |
| Free cash flow margin | 12.9% | n/a |
| Earnings per share (diluted) | -$2.91 | $6.41 |
| Cash | $213.8M | $3.1B |
| Debt | $166K | n/a |
| Price to earnings | n/a | 19.3 |
| Market value | $14B | $25.1B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #72 of 523 · Health care | #60 of 523 · Health care |
Over the years
Questions about Charles River Laboratories International and Incyte
Which is bigger by revenue, Charles River Laboratories International or Incyte?
Incyte is bigger by revenue: $5.1B in fiscal 2025, against $4B for Charles River Laboratories International in fiscal 2025.
Which keeps more of its revenue as profit, Charles River Laboratories International or Incyte?
Charles River Laboratories International had a net margin of -3.6% in fiscal 2025; Incyte had 25.0% in fiscal 2025.
Which grew revenue faster, Charles River Laboratories International or Incyte?
In their latest fiscal years revenue changed by -0.9% at Charles River Laboratories International and +21.2% at Incyte.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.